Clinical trial
Randomized Controlled Trial of Moderate-Intensity Rosuvastatin With Ezetimibe…
NCT03169985 · Samsung Medical Center, Other · Active, not recruiting
Key facts
| NCT number | NCT03169985 |
|---|---|
| Title | Randomized Controlled Trial of Moderate-Intensity Rosuvastatin With Ezetimibe Combination Therapy Versus High-Intensity Rosuvastatin on Progression of Coronary Atherosclerotic Plaque |
| Official title | The Effect of Moderate-intensity Rosuvastatin Plus Ezetimibe Versus High-intensity Rosuvastatin on Coronary Atherosclerotic Plaque by Intravascular Ultrasound (ROSUZET-IVUS Trial) |
| Acronym | Rosuzet-IVUS |
| Lead sponsor | Samsung Medical Center, Other |
| Collaborators | Hanmi Pharmaceutical co., ltd. |
| Status | Active, not recruiting |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Coronary Artery Disease |
| Intervention type | Drug |
| Interventions | Rosuvastatin 10 mg plus ezetimibe 10 mg orally once a day, Rosuvastatin 20 mg orally once a day |
| Enrollment | 280 |
| Start date | Jul 12, 2017 |
| Primary completion | Jan 28, 2027 |
| Completion | Jan 28, 2027 |
| First posted | May 30, 2017 |
| Last update posted | Jul 16, 2025 |
| Countries | South Korea |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: